Compare Invesco DB Agriculture Fund (DBA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Quest Diagnostics Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while Quest Diagnostics Inc trades at $231.38 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 19.3× Invesco DB Agriculture Fund's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Quest Diagnostics Inc for 56 Days on average.
| DBA | DGX | |
|---|---|---|
Market Cap | $1.32B | $25.48B |
Volume | 771,657 | 941,866 |
52-Week High | $29.49 | $247.45 |
52-Week Low | $25.44 | $173.49 |
Typical Hold Time | 24 Days | 56 Days |
Sector | — | Health |
Enterprise Value | — | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.295, down 0.68% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF has delivered strong 12.4% YTD returns, outperforming the S&P 500 in recent months according to Zacks Investment Research (2026-07-30). Recent news highlights agricultural ETF strength driven by weather risks and geopolitical tensions, though the fund carries a relatively high 0.85% expense ratio.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and global demand, but investors face volatility risks from commodity price swings and geopolitical uncertainty. Analyst sentiment remains mixed with Seeking Alpha maintaining a Hold rating (2026-09-22) while noting bullish long-term trends since 2020.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
